Nathalie Wagner
Head Of Preclinical Pharmacology Galderma
Seminars
Wednesday 4th November 2026
Optimizing Dosing Strategies to Enhance Efficacy & Differentiate Dermatology Therapies
11:00 am
- Explain how model-informed drug development (MIDD) approaches, integrating clinical data and quantitative pharmacology methodologies, were applied to support dose selection for nemolizumab in 2 different indications
- Demonstrate the role of body weight as a key intrinsic covariate influencing the PK profile of nemolizumab, and how this finding informed the implementation of a body weight–
- tiered dosing strategy in Prurigo Nodularis versus a fixed dosing regimen in Atopic Dermatitis
